enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. EBGLYSS for eczema: What to know about the newly FDA-approved ...

   www.aol.com/ebglyss-eczema-know-newly-fda...

   A newly approved drug for the treatment of atopic dermatitis could make a big difference to people with moderate-to-severe eczema. Image credit: Sascha Lotz/picture alliance via Getty Images.

3. Abrocitinib - Wikipedia

   en.wikipedia.org/wiki/Abrocitinib

   In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. [9]In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics ...

4. Lebrikizumab - Wikipedia

   en.wikipedia.org/wiki/Lebrikizumab

   Lebrikizumab, sold under the brand name Ebglyss is a humanized monoclonal antibody used for the treatment of atopic dermatitis (atopic eczema). [ 7 ] [ 8 ] It is an interleukin-13 antagonist. [ 7 ] It is given by subcutaneous injection .

5. Delgocitinib - Wikipedia

   en.wikipedia.org/wiki/Delgocitinib

   Delgocitinib, sold under the brand name Corectim among others, is a medication used for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. [3] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis. [3]

6. Dupilumab - Wikipedia

   en.wikipedia.org/wiki/Dupilumab

   [12] [13] It received approval from the US Food and Drug Administration (FDA) for moderate-to-severe atopic dermatitis in 2017, [7] and for asthma in 2018. [4] The FDA considers it to be a first-in-class medication. [14] Dupilumab is the first treatment for eosinophilic esophagitis approved by the U.S. Food and Drug Administration (FDA). [9]

7. Upadacitinib - Wikipedia

   en.wikipedia.org/wiki/Upadacitinib

   Upadacitinib was approved in January 2022, by the FDA for treating adults and children twelve years of age and older with moderate to severe treatment refractory atopic dermatitis. [ 10 ] [ 17 ] Upadacitinib was approved in March 2022, by the FDA for treating adults with moderately to severely active ulcerative colitis who did not respond to ...